General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 211: What percentage of drugs exist as enantiomers?

A. Less than 1%
B. 10%
C. More than 50% (Correct Answer)
D. 100%

Explanation: ### Explanation **1. Why "More than 50%" is Correct:** In pharmacology, chirality (optical isomerism) is a fundamental concept. A drug exists as enantiomers when it contains one or more chiral centers (usually a carbon atom bonded to four different groups). Currently, **more than 50% of drugs** used in clinical practice are chiral. Most of these are synthesized as **racemic mixtures** (a 50:50 mix of two enantiomers), although there is a growing trend toward developing "single-enantiomer" drugs (chiral switching) to improve efficacy and reduce side effects. **2. Why Other Options are Incorrect:** * **Less than 1% / 10%:** These figures are far too low. Most biological targets (receptors, enzymes, transporters) are made of L-amino acids and are themselves chiral. Therefore, drugs are specifically designed or naturally occur as chiral molecules to achieve a "lock and key" fit with these targets. * **100%:** While many drugs are chiral, several important drugs are **achiral** (do not have enantiomers). Examples include simple molecules like ethanol, or drugs with symmetrical structures like paracetamol (acetaminophen) and glycine. **3. High-Yield Clinical Pearls for NEET-PG:** * **Eutomer vs. Distomer:** The enantiomer that produces the desired therapeutic effect is the *eutomer*; the one that is less active or toxic is the *distomer*. * **Thalidomide Tragedy:** A classic example of enantiomer toxicity. The (R)-enantiomer is a sedative, while the (S)-enantiomer is potent teratogen causing phocomelia. * **Chiral Switching:** This involves developing a single enantiomer from a previously racemic drug to gain a patent or clinical advantage. Examples: * **Racemic:** Omeprazole → **Single Enantiomer:** Esomeprazole * **Racemic:** Cetirizine → **Single Enantiomer:** Levocetirizine * **Racemic:** Citalopram → **Single Enantiomer:** Escitalopram * **Hybrid Drugs:** Some drugs are used as racemates because both isomers contribute differently but positively (e.g., **Labetalol** has four isomers acting on alpha and beta receptors).

Question 212: What is the approximate number of patients recruited in phase II clinical trials of a drug?

A. 20-100 (Correct Answer)
B. 100-500
C. 500-1000
D. 1000-5000

Explanation: **Explanation:** The correct answer is **A (20-100)**. In drug development, **Phase II clinical trials** (Therapeutic Exploratory trials) are primarily designed to evaluate the **efficacy** of a drug in a specific patient population and to determine the optimal dose range. While textbooks often cite a range of 100–300 patients for Phase II, NEET-PG and other standard medical exams frequently follow the classification where Phase II is divided into IIa (pilot studies) and IIb (pivotal trials). In many standardized formats, the initial recruitment for Phase II is categorized in the **20-100** range to distinguish it from the larger-scale Phase III trials. **Analysis of Options:** * **A (20-100):** Correct. This represents the initial cohort of patients used to establish proof-of-concept and safety in the target disease group. * **B (100-500):** While some Phase II trials expand to this size, it is more characteristic of the transition between Phase II and Phase III. * **C & D (500-5000):** These large numbers are characteristic of **Phase III (Therapeutic Confirmatory)** trials, which require a massive sample size to achieve statistical significance for efficacy and to detect rarer adverse effects. **High-Yield Clinical Pearls for NEET-PG:** * **Phase I:** Conducted on **Healthy Volunteers** (Exception: Anti-cancer drugs). Focus: Safety and Pharmacokinetics. (N = 20-80). * **Phase II:** Conducted on **Patients**. Focus: **Efficacy** and Dose-finding. * **Phase III:** Multi-centric, Randomized Controlled Trials (RCTs). Focus: Comparison with existing standard treatments. * **Phase IV:** Post-marketing surveillance. Focus: Rare adverse effects and long-term safety. * **Phase 0:** Microdosing studies (Sub-therapeutic doses) to study human pharmacokinetics early.

Question 213: Who synthesized the first H2 receptor blocker in 1972?

A. Asch and Child
B. Sir James Black (Correct Answer)
C. Gaddum and Picarelli
D. Vane

Explanation: **Explanation:** **Sir James Black** is the correct answer. In 1972, he and his team at Smith, Kline & French synthesized **Burimamide**, the first H2 receptor antagonist. This discovery was revolutionary because it proved that histamine receptors were not a single population; while H1 receptors mediated allergic responses, H2 receptors mediated gastric acid secretion. Sir James Black is uniquely significant in pharmacology for developing both the first clinically successful **Beta-blocker (Propranolol)** and the first **H2-blocker (Cimetidine)**, for which he was awarded the Nobel Prize in 1988. **Analysis of Incorrect Options:** * **Asch and Schild (1966):** They are credited with the initial classification of histamine receptors into H1 and H2 based on pharmacological responses, but they did not synthesize the blocking agents. * **Gaddum and Picarelli (1957):** They are famous for classifying **Serotonin (5-HT) receptors** into 'M' (now 5-HT3) and 'D' (now 5-HT2) receptors. * **John Vane:** He won the Nobel Prize for discovering the mechanism of action of **Aspirin** (inhibition of prostaglandin synthesis) and played a key role in the discovery of Prostacyclin. **High-Yield Clinical Pearls for NEET-PG:** * **Cimetidine** was the first H2 blocker used clinically but is now less preferred due to its **enzyme inhibitory** properties (CYP450 inhibitor) and anti-androgenic side effects (gynecomastia). * **Burimamide** was the first synthesized, but it was not orally effective. **Metiamide** followed but caused agranulocytosis. **Cimetidine** was the first safe, blockbuster drug of this class. * Sir James Black is often called the "Father of Analytical Pharmacology."

Question 214: Ketanserin is:

A. A 5-HT1B antagonist
B. A 5-HT2 antagonist (Correct Answer)
C. A 5-HT1A antagonist
D. A 5-HT1P antagonist

Explanation: **Explanation:** **Ketanserin** is a selective antagonist at **5-HT₂ receptors** (specifically the 5-HT₂A subtype). In addition to its serotonergic blockade, it also possesses significant **α₁-adrenergic blocking** properties. The primary mechanism involves blocking 5-HT₂ receptors on vascular smooth muscle and platelets. This leads to vasodilation and inhibition of serotonin-induced platelet aggregation. Clinically, it has been used as an antihypertensive agent, particularly in managing hypertension associated with carcinoid syndrome or pre-eclampsia. **Analysis of Options:** * **Option B (Correct):** Ketanserin is the prototypical 5-HT₂ antagonist. * **Option A (5-HT₁B):** Antagonists here are less clinically common; however, **Sumatriptan** is a well-known *agonist* at 5-HT₁B/₁D receptors used for migraines. * **Option C (5-HT₁A):** **Buspirone** is a partial agonist at this receptor (used for anxiety), while **Way-100635** is a research-grade antagonist. * **Option D (5-HT₁P):** This receptor is primarily located in the enteric nervous system; Ketanserin does not have significant affinity here. **High-Yield Clinical Pearls for NEET-PG:** * **Other 5-HT₂ Antagonists:** Ritanserin (selective 5-HT₂), Cyproheptadine (non-selective 5-HT₂ + H₁ blocker), and Clozapine (atypical antipsychotic). * **Drug of Choice for Carcinoid Syndrome:** While Ketanserin manages symptoms, **Octreotide** (somatostatin analogue) is the drug of choice for symptomatic relief. * **Cyproheptadine** is the specific antidote used for **Serotonin Syndrome**. * Ketanserin also blocks **α₁ receptors**, contributing to its hypotensive effect.

Question 215: What is characteristic of an agonist?

A. Affinity with intrinsic activity of 1 (Correct Answer)
B. Affinity with intrinsic activity of 0
C. Affinity with intrinsic activity of -1
D. None of the above

Explanation: ### Explanation In pharmacology, the interaction between a drug and its receptor is defined by two key parameters: **Affinity** (the ability of a drug to bind to a receptor) and **Intrinsic Activity/Efficacy** (the ability of a drug to activate the receptor and produce a biological response). **Why Option A is Correct:** An **Agonist** is a drug that possesses both affinity and maximal intrinsic activity. By convention, the intrinsic activity (IA) of a full agonist is **1**. This means that upon binding, the drug induces a conformational change in the receptor that triggers the maximum possible biological effect. **Analysis of Incorrect Options:** * **Option B (IA = 0):** This describes an **Antagonist**. An antagonist has affinity (it binds to the receptor) but zero intrinsic activity. It produces no response of its own but prevents an agonist from binding. * **Option C (IA = -1):** This describes an **Inverse Agonist**. These drugs bind to receptors that have "constitutive activity" (spontaneous activity in the absence of a ligand) and suppress this baseline activity, producing an effect opposite to that of an agonist. * **Partial Agonists (Note):** These have affinity but an intrinsic activity between **0 and 1**. **NEET-PG High-Yield Pearls:** 1. **Intrinsic Activity Scale:** * Full Agonist: 1 * Partial Agonist: >0 to <1 * Antagonist: 0 * Inverse Agonist: -1 2. **Clinical Correlation:** A partial agonist (e.g., **Pindolol** or **Buprenorphine**) can act as an antagonist in the presence of a full agonist by displacing it from receptors, a phenomenon known as "dual action." 3. **Potency vs. Efficacy:** Efficacy (Intrinsic Activity) is clinically more important than potency. A drug with higher efficacy is more effective for severe conditions, regardless of the dose required.

Question 216: What is the typical outcome for a drug after undergoing Phase II biotransformation reactions?

A. Less bioreactive
B. Increased bioavailability
C. Increased water solubility (Correct Answer)
D. Increased lipid solubility

Explanation: ### Explanation **Phase II biotransformation reactions** (also known as synthetic or conjugation reactions) involve the attachment of an endogenous polar group (such as glucuronic acid, sulfate, or glutathione) to a drug or its Phase I metabolite. **1. Why "Increased water solubility" is correct:** The primary physiological goal of Phase II metabolism is to make the drug more **polar and hydrophilic (water-soluble)** [1], [2]. By increasing water solubility, the body ensures that the drug cannot easily diffuse back across the renal tubular membranes (reabsorption) and is instead efficiently excreted in the urine or bile [2]. **2. Analysis of Incorrect Options:** * **A. Less bioreactive:** While many drugs are inactivated during Phase II, this is not a universal rule [1], [2]. Some drugs are converted into active metabolites (e.g., Morphine-6-glucuronide is more potent than morphine) [1]. * **B. Increased bioavailability:** Metabolism typically *decreases* bioavailability (especially via the first-pass effect). Bioavailability refers to the fraction of the drug reaching systemic circulation; metabolism occurs after or during this process. * **D. Increased lipid solubility:** This is the opposite of the goal. Lipid-soluble drugs are easily reabsorbed by the kidneys and remain in the body longer. Phase II reactions specifically aim to terminate this lipophilicity. **3. NEET-PG High-Yield Clinical Pearls:** * **Glucuronidation** is the most common Phase II reaction. It is catalyzed by **UGT enzymes**. * **Exception to Inactivation:** Morphine-6-glucuronide (active) and Minoxidil sulfate (active). * **Gray Baby Syndrome:** Occurs in neonates due to a deficiency of UDP-glucuronyltransferase, leading to toxic accumulation of Chloramphenicol. * **Acetylation:** Shows genetic polymorphism (Fast vs. Slow acetylators). Drugs following this path include **S**ulfonamides, **I**soniazid, **P**rocainamide, and **H**ydralazine (Mnemonic: **SHIP**).

Question 217: Which of the following are NOT typically administered intradermally?

A. BCG vaccine
B. Insulin (Correct Answer)
C. Test dose of drugs
D. Mantoux test

Explanation: **Explanation:** The **Intradermal (ID)** route involves injecting a drug into the dermis, the vascular layer of skin just below the epidermis. This route is characterized by slow absorption and is primarily used for diagnostic purposes or specific immunizations. **Why Insulin is the Correct Answer:** Insulin is typically administered via the **Subcutaneous (SC)** route. The subcutaneous tissue (fatty layer) has fewer blood vessels than muscle but more than the dermis, allowing for a slow, sustained, and predictable absorption rate. Injecting insulin intradermally would result in inconsistent absorption and potential skin irritation, while intramuscular injection would cause it to be absorbed too rapidly, risking hypoglycemia. **Analysis of Incorrect Options:** * **BCG Vaccine:** This is the classic example of an ID injection. It is administered over the left deltoid to induce a local cellular immune response, leaving a characteristic permanent scar. * **Test Dose of Drugs:** Sensitivity testing (e.g., for Penicillin) is done intradermally to observe for immediate hypersensitivity reactions (wheal and flare) while minimizing systemic exposure to the allergen. * **Mantoux Test:** Also known as the Tuberculin Skin Test (TST), it uses the ID route to inject PPD (Purified Protein Derivative) to screen for tuberculosis infection. **High-Yield NEET-PG Pearls:** * **Angle of Injection:** ID injections are given at a **10–15 degree angle** using a 26-27 gauge needle (tuberculin syringe). * **Volume:** The maximum volume for an ID injection is very small, usually **0.1 ml**. * **Rabies Vaccine:** Modern Post-exposure Prophylaxis (PEP) can be given via the ID route (Updated Thai Red Cross Regimen) to save costs in resource-limited settings. * **Insulin Sites:** Common SC sites include the abdomen (fastest absorption), thighs, and upper arms. Always rotate sites to prevent **lipodystrophy**.

Question 218: Which of the following routes of administration is shown in the given diagram?

A. Intradermal (Correct Answer)
B. Subcutaneous
C. Intramuscular
D. Intravenous

Explanation: ***Intradermal*** - Characterized by a **shallow needle angle of 10-15°** with the **needle tip positioned in the dermis** layer of the skin. - Results in **wheal or bleb formation** at the injection site due to the limited space in the dermal layer. *Subcutaneous* - Involves a **45° needle angle** with injection into the **subcutaneous tissue** beneath the dermis. - Uses **longer needles** than intradermal and does not produce wheal formation due to the loose connective tissue. *Intramuscular* - Requires a **90° needle angle** with **deeper penetration** into the muscle tissue. - Uses **longer needles (1-1.5 inches)** and targets muscles like the **deltoid** or **gluteus maximus**. *Intravenous* - Involves **direct insertion into a vein** with the needle **parallel to the vessel**. - Requires **visualization or palpation of veins** and immediate blood return upon needle insertion.

Question 219: What is true about plasma half-life?

A. Is the same as bioavailability
B. It is directly proportional to clearance
C. It is inversely proportional to volume of distribution
D. Half-life remains constant for drugs eliminated by first-order kinetics (Correct Answer)

Explanation: **Explanation:** The plasma half-life ($t_{1/2}$) is the time required for the plasma concentration of a drug to be reduced by 50%. This concept is governed by the formula: **$t_{1/2} = \frac{0.693 \times V_d}{CL}$** **Why Option D is Correct:** Most drugs follow **First-Order Kinetics**, where a constant *fraction* of the drug is eliminated per unit of time. In this model, the rate of elimination is directly proportional to the plasma concentration. Because clearance ($CL$) and volume of distribution ($V_d$) remain constant, the **half-life remains constant** regardless of the dose administered. **Analysis of Incorrect Options:** * **Option A:** Bioavailability refers to the fraction of an administered dose that reaches the systemic circulation unchanged. It is unrelated to the rate of elimination (half-life). * **Option B:** According to the formula, half-life is **inversely proportional** to clearance ($CL$). If clearance increases (e.g., enzyme induction), the half-life decreases. * **Option C:** Half-life is **directly proportional** to the Volume of Distribution ($V_d$). If a drug is widely distributed in tissues (high $V_d$), it stays in the body longer, increasing the half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Steady State:** It takes approximately **4 to 5 half-lives** to reach a steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body. * **Zero-Order Kinetics:** For drugs like **Aspirin (high dose), Phenytoin, and Ethanol**, the half-life is *not* constant; it increases with the dose because elimination mechanisms become saturated. * **Rule of Thumb:** After 1 half-life, 50% of the drug remains; after 2, 25%; after 3, 12.5%; and after 4, 6.25%.

Question 220: Which of the following is NOT a local route of drug administration?

A. Topical
B. Intra-articular
C. Oral (Correct Answer)
D. Intra-aural

Explanation: ### Explanation **Concept Overview:** Routes of drug administration are broadly classified into **Local** and **Systemic**. * **Local routes** are used when a drug is applied to a specific site for a localized effect, minimizing systemic absorption and side effects. * **Systemic routes** involve the drug entering the bloodstream to be distributed throughout the body to reach the target organ. **Why Oral is the Correct Answer:** The **Oral route** is a **Systemic (Enteral) route**. When a drug is swallowed, it is absorbed through the gastrointestinal mucosa into the portal circulation, undergoes first-pass metabolism in the liver, and then enters the systemic circulation to exert its effect. Therefore, it is not a local route. **Analysis of Incorrect Options:** * **Topical (A):** Involves application to external surfaces like skin or mucous membranes (e.g., ointments, eye drops) for a localized effect at the site of application. * **Intra-articular (B):** Involves injecting the drug directly into a joint space (e.g., steroids for arthritis). The drug acts locally on the joint tissues. * **Intra-aural (D):** Refers to the administration of drops into the ear canal to treat local infections or inflammation. **NEET-PG High-Yield Pearls:** 1. **First-Pass Metabolism:** Oral and Rectal (partial) routes undergo first-pass metabolism, whereas Sublingual and Parenteral routes bypass it. 2. **Intrathecal Route:** Often confused with systemic; it is a **local route** for the CNS (e.g., spinal anesthesia, amphotericin B for meningitis) as it bypasses the Blood-Brain Barrier. 3. **Bioavailability:** The oral route generally has lower bioavailability compared to IV (100%) due to incomplete absorption and first-pass effect.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free